Rare Disease Drug Candidate ‘Sonepeglutide’

“Possible Reflection in Second Quarter Results”

It has been revealed that Hanmi Pharmaceutical has received an upfront payment of 75 million dollars (approximately 112.9 billion won) from global pharmaceutical company Eli Lilly, according to the license agreement for the rare disease drug candidate ‘Sonepeglutide’ (project name: LAPS GLP-2 analog).


Exterior view of Hanmi Pharmaceutical headquarters. Hanmi Pharmaceutical

Exterior view of Hanmi Pharmaceutical headquarters. Hanmi Pharmaceutical

View original image

According to industry sources on July 1, Hanmi Pharmaceutical received the confirmed payment of 75 million dollars (about 112.9 billion won) from Eli Lilly the previous day under the license agreement. This amount does not exclude withholding tax under the Korea-US Tax Treaty.


This agreement grants Eli Lilly the exclusive rights to develop, manufacture, and commercialize Sonepeglutide worldwide, except for South Korea. Hanmi Pharmaceutical will continue to conduct the ongoing global Phase 2 clinical trial for short bowel syndrome (SBS) up to its completion. Based on preclinical and clinical data, Eli Lilly plans to proceed with additional clinical trials thereafter.


Going forward, Hanmi Pharmaceutical may receive up to an additional 1.185 billion dollars (approximately 1.7844 trillion won) from Eli Lilly, depending on the achievement of clinical development, regulatory approval, and commercialization milestones. After product launch, Hanmi Pharmaceutical will also receive separate royalty payments.


A Hanmi Pharmaceutical official stated, “We have received a non-refundable upfront payment from Eli Lilly as part of the Sonepeglutide license agreement,” adding, “This payment may be reflected in the second quarter results.”



The industry points to Hanmi’s sustained-release platform technology, ‘LAPSCOVERY,’ as the key factor behind the out-licensing of a rare disease candidate at this scale. LAPSCOVERY has been applied to five candidates, including the anti-obesity drug ‘Efeglenatide’ and the neutropenia treatment ‘Rolontis,’ and they are currently being developed in global clinical stages.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing